Medicinal use of leonurine for menopause disease

A technology of motherwort and disease, applied in the field of medicine, can solve problems such as increasing myocardial infarction and thrombosis

Active Publication Date: 2010-06-16
李晓祥
View PDF1 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no drug with small side effects and significant curative effect, and estrogen replacement therapy (hormone replacement treatment, HRT) is commonly used clinically, but adverse reactions caused by HRT continue to appear, such as estrogen and progesterone increase myocardial infarction, stroke, The long-term use of HRT has been questioned internationally due to the risk of breast cancer and thrombosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal use of leonurine for menopause disease
  • Medicinal use of leonurine for menopause disease
  • Medicinal use of leonurine for menopause disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Embodiment 1: Leonurine has effect on serum TSH and FT of climacteric model rats 3 、FT 4 Impact

[0020] According to the above experiment, motherwort has no effect on serum TSH, FT of climacteric model rats. 3 、FT 4 The results can be seen in Table 1.

[0021] Table 1 Leonurine has effect on TSH and FT of menopausal rats 3 、FT 4 Impact( n=8)

[0022]

[0023] ▲ P<0o5vs young control group, *p<0.05vs menopausal model group

[0024] Table 1 illustrates the TSH and FT of rats in the menopausal model group 3 Compared with the young control group, the secretion level of ▲ P3 Both medium and high doses of motherwort significantly reduced TSH and FT in model group rats 3 Level (*p4 The level has nothing to do with menopausal syndrome, but motherwortine has no effect on FT 4 level has almost no effect. It shows that motherwort can significantly prevent, relieve or treat menopausal syndrome.

Embodiment 2

[0025] Example 2: Effects of Leonurine on Hypothalamic NE, DA, 5-HT, 5-HIAA of Climacteric Model Rats The results are shown in Tables 2 and 3.

[0026] The influence of table 2 leonurine on NE, DA content of climacteric rats ( n=8)

[0027]

[0028] ▲ P<0.05vs youth control group, *p<0.05vs menopausal model group

[0029] Table 2 shows that the NE secretion level of rats in the climacteric model group is significantly lower than that of the young control group ( ▲ P<0.05vs youth control group); Leonurine can increase the NE level of model group rats, and high dose of Leonurine can significantly improve the NE level of model group rats (*p<0.05vs climacteric model group); There was no significant difference in the DA level of mice. It shows that motherwort can significantly prevent, relieve or treat menopausal syndrome.

[0030] The effect of table 3 Leonurine on 5-HT, 5-HIAA content of climacteric rats ( n=8)

[0031]

[0032] ▲ P<0.05vs youth control group, *...

Embodiment 3

[0034] Embodiment 3: Leonurine has effect on serum E of climacteric model rats 2 , the influence of P

[0035] According to the above experiment, motherwort has effect on serum E of climacteric model rats. 2 , P, the results are shown in Table 4.

[0036] Table 4 Leonurine has effect on menopausal rat serum E 2 , the effect of P ( n=8)

[0037]

[0038] ▲ P<0.05vs youth control group, *p<0.05vs menopausal model group

[0039] Table 4 illustrates the climacteric model group rat E 2 and P secretion levels were significantly lower than those of the young control group ( ▲p2 Secretion levels, high doses of motherwort significantly increased the E of model group animals 2 and P secretion level (*p<0.05 vs the menopausal model group), this result suggests that motherwort relieves the symptoms of menopausal syndrome and can increase the levels of estrogen and progesterone in menopausal rats.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to medicinal use of leonurine for menopause disease, and in particular provides the medicinal use of the leonurine or pharmaceutical salts thereof for preventing or treating menopause syndrome and menopause syndrome related diseases.

Description

Technical field: [0001] The invention belongs to the field of medicine and relates to a new medical application of motherwortine. Specifically, the present invention provides a new application of leonurine for preventing or treating climacteric syndrome and diseases related to climacteric syndrome. Background technique: [0002] Leonurus, also known as Leonurus heterophyllus Sweet, is a plant of the genus Leonurus in the Lamiaceae family. It is the most common medicinal plant in my country. Its Latin scientific name is Leonurus heterophyllus Sweet. Its function and indication are recorded in Chinese medicine literature as promoting blood circulation. , dispelling blood stasis, regulating menstruation, and eliminating water, it is known as "the holy medicine for blood vessels" and "good prescription for labor". [0003] Leonurine is the main active substance of Motherwort, which only contains less than 5‰ in the crude drug, and the extraction process is relatively complicated...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/235A61P15/12
Inventor 李晓祥李德刚徐自奥王显芹李爱玲
Owner 李晓祥
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap